Halozyme Therapeutics Past Earnings Performance
Past criteria checks 4/6
Halozyme Therapeutics has been growing earnings at an average annual rate of 46.9%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 35.1% per year. Halozyme Therapeutics's return on equity is 336%, and it has net margins of 34%.
Key information
46.9%
Earnings growth rate
47.3%
EPS growth rate
Biotechs Industry Growth | 11.5% |
Revenue growth rate | 35.1% |
Return on equity | 336.0% |
Net Margin | 34.0% |
Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Halozyme Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 829 | 282 | 149 | 0 |
30 Sep 23 | 781 | 254 | 127 | 0 |
30 Jun 23 | 774 | 234 | 127 | 0 |
31 Mar 23 | 705 | 182 | 145 | 0 |
31 Dec 22 | 660 | 202 | 122 | 0 |
30 Sep 22 | 581 | 211 | 120 | 0 |
30 Jun 22 | 487 | 366 | 98 | 0 |
31 Mar 22 | 472 | 435 | 53 | 0 |
31 Dec 21 | 443 | 403 | 50 | 0 |
30 Sep 21 | 463 | 409 | 47 | 0 |
30 Jun 21 | 412 | 229 | 46 | 0 |
31 Mar 21 | 331 | 163 | 44 | 0 |
31 Dec 20 | 268 | 129 | 46 | 0 |
30 Sep 20 | 200 | 22 | 48 | 0 |
30 Jun 20 | 180 | -40 | 54 | 0 |
31 Mar 20 | 164 | -80 | 61 | 0 |
31 Dec 19 | 196 | -72 | 77 | 0 |
30 Sep 19 | 203 | -40 | 71 | 0 |
30 Jun 19 | 182 | -43 | 68 | 0 |
31 Mar 19 | 178 | -51 | 65 | 0 |
31 Dec 18 | 152 | -80 | 61 | 0 |
30 Sep 18 | 281 | 46 | 58 | 0 |
30 Jun 18 | 319 | 76 | 56 | 0 |
31 Mar 18 | 318 | 68 | 55 | 0 |
31 Dec 17 | 317 | 63 | 54 | 0 |
30 Sep 17 | 166 | -88 | 51 | 0 |
30 Jun 17 | 134 | -120 | 50 | 0 |
31 Mar 17 | 134 | -116 | 48 | 0 |
31 Dec 16 | 147 | -103 | 46 | 0 |
30 Sep 16 | 160 | -71 | 44 | 0 |
30 Jun 16 | 149 | -67 | 43 | 0 |
31 Mar 16 | 159 | -37 | 41 | 0 |
31 Dec 15 | 135 | -32 | 40 | 0 |
30 Sep 15 | 113 | -42 | 38 | 0 |
30 Jun 15 | 107 | -38 | 36 | 0 |
31 Mar 15 | 82 | -57 | 35 | 0 |
31 Dec 14 | 75 | -68 | 36 | 0 |
30 Sep 14 | 57 | -85 | 37 | 0 |
30 Jun 14 | 59 | -84 | 36 | 0 |
31 Mar 14 | 55 | -91 | 35 | 0 |
31 Dec 13 | 55 | -83 | 32 | 0 |
30 Sep 13 | 64 | -66 | 30 | 0 |
30 Jun 13 | 53 | -67 | 27 | 0 |
Quality Earnings: 0J2O has high quality earnings.
Growing Profit Margin: 0J2O's current net profit margins (34%) are higher than last year (30.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0J2O has become profitable over the past 5 years, growing earnings by 46.9% per year.
Accelerating Growth: 0J2O's earnings growth over the past year (39.3%) is below its 5-year average (46.9% per year).
Earnings vs Industry: 0J2O earnings growth over the past year (39.3%) exceeded the Biotechs industry -11.5%.
Return on Equity
High ROE: Whilst 0J2O's Return on Equity (336%) is outstanding, this metric is skewed due to their high level of debt.